Evidence map›Paper›PMID 31772723›Full record

ArticleNano research2018

Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.

Danielle M Valcourt, Jenna Harris, Rachel S Riley, Megan Dang, Jianxin Wang, Emily S Day

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Membrane-modified lipid nanoparticles for RNA delivery.Molecular therapy. Methods & clinical development · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Combination cancer imaging and phototherapy mediated by membrane-wrapped nanoparticles.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Danielle M Valcourt161 Colburn Lab, Department of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.
Jenna Harris201 DuPont Hall, Department of Materials Science & Engineering, University of Delaware, Newark, DE 19716, USA.
Rachel S Riley161 Colburn Lab, Department of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.
Megan Dang161 Colburn Lab, Department of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.
Jianxin Wang161 Colburn Lab, Department of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.
Emily S Day161 Colburn Lab, Department of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.

Funding

Maximizing the delivery and efficacy of miRNA therapeutics through nanocarrier designR35GM119659 · NIGMS · UNIVERSITY OF DELAWARE · PI DAY, EMILY S · 2016 to 2020
$2.0M
NIGMS NIH HHS R35 GM119659
6 · The paper itself

Abstract

Since the emergence of cancer nanomedicine, researchers have had intense interest in developing nanoparticles (NPs) that can specifically target diseased sites while avoiding healthy tissue to mitigate the off-target effects seen with conventional treatments like chemotherapy. Initial endeavors focused on the bioconjugation of targeting agents to NPs, and more recently, researchers have begun to develop biomimetic NP platforms that can avoid immune recognition to maximally accumulate in tumors. In this review, we describe the advantages and limitations of each of these targeting strategies. First, we review developments in bioconjugation strategies, where NPs are coated with biomolecules such as antibodies, aptamers, peptides, and small molecules to enable cell-specific binding. While bioconjugated NPs offer many exciting features and have improved pharmacokinetics and biodistribution relative to unmodified NPs, they are still recognized by the body as "foreign", resulting in their clearance by the mononuclear phagocytic system (MPS). To overcome this limitation, researchers have recently begun to investigate biomimetic approaches that can hide NPs from immune recognition and reduce clearance by the MPS. These biomimetic NPs fall into two distinct categories: synthetic NPs that present naturally occurring structures, and NPs that are completely disguised by natural structures. Overall, bioconjugated and biomimetic NPs have substantial potential to improve upon conventional treatments by reducing off-target effects through site-specific delivery, and they show great promise for future standards of care. Here, we provide a summary of each strategy, discuss considerations for their design moving forward, and highlight their potential clinical impact on cancer therapy.

Indexed as

bioconjugationbiomimicrycancerdeliverynanoparticlestargeting

Identifiers

PMID31772723
PMCPMC6879063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.